CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
OKLAHOMA CITY, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of...
All-time high revenues and EBITDA profitability for 2022COPENHAGEN, Denmark, January 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) today reported...
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant...
Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New...
Full year 2022 commercial revenue expected to be between $17.0 million and $17.2 million Finished 2022 with approximately $140 million...
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for...
BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell...
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna...
High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based...
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by...
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of InertiaMORRISVILLE, N.C., Jan....
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single...
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M,...
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with...
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral...
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech...
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug ApprovalsNEW YORK,...